Navigating India’s Rapidly Growing Obesity Market

Authors: Monica Gangwani, Executive Director India, Advisory Services, APAC Consulting; Gaurav Kolhekar, Senior Consultant, APAC Consulting; Utkarsh Sahu, Analyst, APAC Consulting

India’s obesity market is rapidly expanding, driven by economic growth and lifestyle changes that have led to increased consumption of processed and sugary foods. As of 2024, approximately 92 million Indians are classified as obese, with a higher prevalence in urban areas. However, rural areas are experiencing a faster growth rate in obesity, projected to equal urban rates by 2031. The unique “thin-fat” obesity phenotype in Indians, characterized by a higher body fat percentage in a smaller frame, complicates the application of global obesity standards, necessitating region-specific criteria.

The Indian market for anti-obesity drugs is poised for significant growth, with both international and domestic companies planning new launches. Currently, the market relies heavily on off-label use of diabetes drugs due to limited approved options. The introduction of new drugs like Wegovy and Zepbound, along with domestic biosimilars, is expected to drive a transition to approved treatments. Strategic pricing and manufacturing capacity will be crucial to meet the rising demand, particularly in rural areas. Comprehensive long-term trials and real-world evidence will be essential to build confidence among healthcare professionals and patients.

Complete the form to download the full white paper.